Rajbhandari J, Fernandez CJ, Agarwal M, et al. Diabetic heart disease: a clinical update. World J Diabetes. 2021;12(4):383–406. https://doi.org/10.4239/wjd.v12.i4.383.

Article  PubMed  PubMed Central  Google Scholar 

Mahalingasivam AA, Jespersen AK, Ejskjaer N, et al. The co-existence of peripheral and vestibular neuropathy in diabetes: a cross-sectional study. Eur Arch Otorhinolaryngol. 2024;281:663–72. https://doi.org/10.1007/s00405-023-08130-6.

Article  PubMed  Google Scholar 

Rasmussen NH, Dal J, den Bergh J, et al. Increased risk of falls, Fall-related injuries and fractures in people with type 1 and type 2 Diabetes - A nationwide cohort study. Curr Drug Saf. 2021;16:52–61. https://doi.org/10.2174/1574886315666200908110058.

Article  CAS  PubMed  Google Scholar 

Rasmussen NH, Dal J. Falls and fractures in diabetes-more than bone fragility. Curr Osteoporos Rep. 2019;17:147–56. https://doi.org/10.1007/s11914-019-00513-1.

Article  PubMed  Google Scholar 

Rasmussen NH-H, Dal J, Kvist AV, et al. Bone parameters in T1D and T2D assessed by DXA and HR-pQCT - a cross-sectional study: the DIAFALL study. Bone. 2023;172:116753. https://doi.org/10.1016/j.bone.2023.116753.

Article  PubMed  Google Scholar 

Candido R, Srivastava P, Cooper ME, Burrell LM. Diabetes mellitus: a cardiovascular disease. Curr Opin Investig Drugs. 2003;4:1088–94.

PubMed  Google Scholar 

De Rosa S, Arcidiacono B, Chiefari E, et al. Type 2 diabetes mellitus and cardiovascular disease: genetic and epigenetic links. Front Endocrinol (Lausanne). 2018;9:2. https://doi.org/10.3389/fendo.2018.00002.

Article  PubMed  Google Scholar 

Blackwood J. Cognitive function and falls in older adults with type 2 diabetes mellitus. J Geriatr Phys Ther. 2019;42:E91–6. https://doi.org/10.1519/JPT.0000000000000209.

Article  PubMed  Google Scholar 

Viggers R, Rasmussen NH-H, Vestergaard P. Effects of incretin therapy on skeletal health in type 2 Diabetes-a systematic review. JBMR Plus. 2023;7:e10817. https://doi.org/10.1002/jbm4.10817.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696–705. https://doi.org/10.1016/S0140-6736(06)69705-5.

Article  CAS  PubMed  Google Scholar 

Scheen AJ. Clinical pharmacology of antidiabetic drugs: what can be expected of their use? Presse Med. 2023;52:104158. https://doi.org/10.1016/j.lpm.2022.104158.

Article  PubMed  Google Scholar 

Abdul-Ghani MA, Williams K, Kanat M, et al. Insulin vs GLP-1 analogues in poorly controlled type 2 diabetic subjects on oral therapy: a meta-analysis. J Endocrinol Invest. 2013;36:168–73. https://doi.org/10.3275/8367.

Article  CAS  PubMed  Google Scholar 

Nauck MA, Quast DR, Wefers J, Pfeiffer AFH. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update. Diabetes Obes Metab 23 Suppl. 2021;3:5–29. https://doi.org/10.1111/dom.14496.

Article  CAS  Google Scholar 

Scheen AJ. Dual GIP/GLP-1 receptor agonists: new advances for treating type-2 diabetes. Ann Endocrinol (Paris). 2023;84:316–21. https://doi.org/10.1016/j.ando.2022.12.423.

Article  PubMed  Google Scholar 

De Block C, Bailey C, Wysham C, et al. Tirzepatide for the treatment of adults with type 2 diabetes: an endocrine perspective. Diabetes Obes Metab. 2023;25:3–17. https://doi.org/10.1111/dom.14831.

Article  CAS  PubMed  Google Scholar 

Giugliano D, Scappaticcio L, Longo M, et al. GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. Cardiovasc Diabetol. 2021;20:189. https://doi.org/10.1186/s12933-021-01366-8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9:653–62. https://doi.org/10.1016/S2213-8587(21)00203-5.

Article  CAS  PubMed  Google Scholar 

Alejandro R. Jadad RAMDCCJDJMRDJGHJM Assessing the quality of reports of randomized clinical trials: is blinding necessary? https://scholar.google.com/citations?view_op=view_citation%26hl=en%26user=pjha-gkAAAAJ%26citation_for_view=pjha-gkAAAAJ:_xSYboBqXhAC. Accessed 6 Mar 2025.

GA Wells BSDOJPVWMLPT The Newcastle-Ottawa Scale (NOS). https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 6 Mar 2025.

GRADE. https://www.gradeworkinggroup.org/. Accessed 6 Mar 2025.

Chen K, Wu R, Mo B et al. Comparison between liraglutide alone and liraglutide in combination with insulin on osteoporotic rats and their effect on bone mineral density.

Wang R, Na H, Cheng S, et al. Effects of glucagonlike peptide-1 receptor agonists on fracture healing in a rat osteoporotic model. Exp Ther Med. 2023. https://doi.org/10.3892/etm.2023.12111.

Article  PubMed  PubMed Central  Google Scholar 

Cheng Y, Liu P, Xiang Q, et al. Glucagon-like peptide-1 attenuates diabetes-associated osteoporosis in ZDF rat, possibly through the RAGE pathway. BMC Musculoskelet Disord. 2022. https://doi.org/10.1186/s12891-022-05396-5.

Article  PubMed  PubMed Central  Google Scholar 

Mieczkowska A, Millar P, Chappard D, et al. Dapagliflozin and liraglutide therapies rapidly enhanced bone material properties and matrix biomechanics at bone formation site in a type 2 diabetic mouse model. Calcif Tissue Int. 2020;107:281–93. https://doi.org/10.1007/s00223-020-00720-4.

Article  CAS  PubMed  Google Scholar 

Li Y, Fu H, Wang H, et al. GLP-1 promotes osteogenic differentiation of human ADSCs via the Wnt/GSK-3β/β-catenin pathway. Mol Cell Endocrinol. 2020. https://doi.org/10.1016/j.mce.2020.110921.

Article  PubMed  PubMed Central  Google Scholar 

Abo-Elenin MHH, Kamel R, Nofal S, Ahmed AAE. The crucial role of beta-catenin in the osteoprotective effect of semaglutide in an ovariectomized rat model of osteoporosis. Naunyn Schmiedebergs Arch Pharmacol. 2024. https://doi.org/10.1007/s00210-024-03378-z.

Article  PubMed  PubMed Central  Google Scholar 

Lv F, Cai X, Lin C, et al. Effects of semaglutide and tirzepatide on bone metabolism in type 2 diabetic mice. Pharmaceuticals. 2024. https://doi.org/10.3390/ph17121655.

Article  PubMed  PubMed Central  Google Scholar 

Deng Y, Zhu W, Anhua lin, et al. Exendin-4 promotes bone formation in diabetic States via HDAC1-Wnt/β-catenin axis. Biochem Biophys Res Commun. 2021;544:8–14. https://doi.org/10.1016/j.bbrc.2021.01.039.

Article  CAS  PubMed  Google Scholar 

Jensen SBK, Sørensen V, Sandsdal RM, et al. Bone health after exercise alone, GLP-1 receptor agonist treatment, or combination treatment: a secondary analysis of a randomized clinical trial. JAMA Netw Open. 2024;e2416775. https://doi.org/10.1001/jamanetworkopen.2024.16775.

Article  PubMed  PubMed Central  Google Scholar 

Cai TT, Li HQ, Jiang LL, et al. Effects of GLP-1 receptor agonists on bone mineral density in patients with type 2 diabetes mellitus: a 52-week clinical study. BioMed Res Int. 2021. https://doi.org/10.1155/2021/3361309.

Article  PubMed  PubMed Central  Google Scholar 

Hansen MS, Wölfel EM, Jeromdesella S et al. (2024) Once-weekly semaglutide versus placebo in adults with increased fracture risk: a randomised, double-blinded, two-centre, phase 2 trial. EClinicalMedicine 72:. https://doi.org/10.1016/j.eclinm.2024.102624

Akyay OZ, Canturk Z, Selek A, et al. The effects of exenatide and insulin glargine treatments on bone turnover markers and bone mineral density in postmenopausal patients with type 2 diabetes mellitus. Medicine (Baltimore). 2023;102:E35394. https://doi.org/10.1097/MD.0000000000035394.

Article  CAS  PubMed  Google Scholar 

Hygum K, Harsløf T, Jørgensen NR, et al. Bone resorption is unchanged by liraglutide in type 2 diabetes patients: a randomised controlled trial. Bone. 2020. https://doi.org/10.1016/j.bone.2019.115197.

Article  PubMed